



**Paul G Richardson**

**Contact**

Paul G Richardson

## Publications (3)

Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. *Lancet Haematol* 2022; 9:e403–e414.

Richardson P, Goldschmidt H, Harousseau J, Dytfeld D, Mellqvist U, Chng W, Hou J, Bergsagel P, Riva E, Leleu X, Bladé J, Driessen C, Quach H, Ocio E, Vesole D, Waage A, Laubach J, Munshi N, Gay F, Dimopoulos M, Rajkumar S, Mateos M, Cook G, Nahi H, Harrison S, Sezer O, Holstein S, Zweegman S, Usmani S, Boccadoro M, Hari P, Kaiser M, Costa L, Beksac M, Maiolino A, Leal da Costa F, Sidana S, Jurczyszyn A, Facon T, Durie B, Yong K, Martin T, Schjesvold F, Terpos E, Mikhael J, Ludwig H, Bahlis N, Zamagni E, Davies F, San Miguel J, Kumar S, Raje N, van de Donk N, Lonial S, Berdeja J, Hungria V, Baz R, Weisel K, Vangsted A, Fonseca R, Engelhardt M, Sonneveld P, Einsele H, João C, Anderson K, Hájek R, Lentzsch S, Kristinsson S, Cavo M, Moreau P. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol* 2021; 22:e105–e118.

Downey-Kopyscinski S, Overkleeft H, Driessen C, Richardson P, Mitsiades C, Florea B, Bhatt A, Gautier M, Daily E, Kisselev A. An inhibitor of proteasome  $\beta$ 2 sites sensitizes myeloma cells to immunoproteasome inhibitors. *Blood Adv* 2018; 2:2443–2451.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)